Nitric BioTherapeutics, Inc. announced the initiation of a Phase II clinical trial of the company’s proprietary drug/device combination, which delivers terbinafine via the process of iontophoresis for the treatment of onychomycosis. Onychomycosis is commonly known as toenail fungus. Nitric Bio’s proprietary drug/device combination delivers very high doses of a unique formulation of terbinafine, the most effective medication used to treat onychomycosis, directly to the site of the infection – on, around and under the toenail.

Read the full story here

Mesynthes has introduced a tissue substitute for people suffering from tissue damage, burns and reconstructive surgeries. The company’s Endoform Dermal Template is an FDA approved ready-to-use tissue substitute that can be used for wound care and dermal reconstruction. The product will improve the rate and quality of healing. Mesynthes is also developing Endoform Infection Control for the prevention of infection if there is a high risk of post-operative infection.

NanoVibronix has announced that following its initial success with the first generation PainShield device for pain therapy, especially for the severe pain associated with Trigeminal Neuralgia, NanoVibronix presents its second generation PainShield with additional features for the therapy of chronic pain and wounds. PainShield is a small, portable device that produces low frequency, low intensity ultrasonic waves for healing of soft tissue such as tendon, chronic wounds and neuropathic pain.

Read the full story here

Derma Sciences has received CE mark for Algicell Ag wound dressings for use in the EU. Algicell Ag is an antimicrobial silver alginate dressing that delivers 1.4% ionic silver at a slow consistent release rate for broad-spectrum efficacy. Derma Sciences claimed that Algicell Ag provides advanced bactericidal action with kill rates of approximately 99.99%, while absorbing approximately 16% more exudates than the leading competitive product.

Read the full story here

United EcoEnergy Corp. has announced that its wholly-owned portfolio company, Epic Wound Care, Inc. has signed an international distribution agreement with Coreva Health Science LLC (Coreva) to distribute Epic’s Hemostyp(TM), under the private label ActCel. Hemostyp is an innovative gauze product designed for use on any wound where bleeding is still present. Upon contact with moisture, the gauze forms a gel-like substance that acts as a homeostatic agent to stop the bleeding quickly.

ZymoGenetics Inc. has presented results at the American Burn Association annual meeting from a clinical trial with RECOTHROM™ Thrombin, a topical (Recombinant) administered by spray device to burn wound excision sites. The study revealed that the topical application of RECOTHROM using a pump spray device was well tolerated and it demonstrated a similar safety profile and rate of antibody formation to that observed in the rThrombin Phase 3 clinical trial.

As skin cancer cases continue to rise, the worldwide deployment of In Vivo Reflectance Confocal Microscopy (RCM) (Confocal Imaging) technology – which produces digital images of a patient’s skin with cellular detail similar to that obtained from histology of surgical biopsies – can help healthcare practitioners both speed and improve their clinical judgments and assist in monitoring treatment. In support of RCM technology, the world’s first available comprehensive atlas detailing the technology has been published.

Reflectance Confocal Microscopy of Cutaneous Tumors: An Atlas with Clinical, Dermoscopic and Histological Correlations (Salvador González, Melissa Gill, and Allan C. Halpern, Editors; Informa Healthcare, Publisher), is a comprehensive, full-color atlas detailing the potential of RCM technology and its possible applications for clinical practitioners. The hard-cover first edition atlas totals 280-pages.

Specifically, In Vivo Reflectance Confocal Microscopy allows optical sectioning of an area of skin without physical sectioning, assisting dermatologists to examine detailed features of a skin lesion without taking a biopsy specimen. RCM technology can also assist dermatopathologists to determine the best location for a section and dermatological surgeons to determine the margins of a lesion to be excised.

More information is available here.